MARKET

MLND

MLND

Millendo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.840
-0.050
-2.65%
Opening 10:28 08/12 EDT
OPEN
1.870
PREV CLOSE
1.890
HIGH
1.900
LOW
1.810
VOLUME
119.11K
TURNOVER
--
52 WEEK HIGH
9.88
52 WEEK LOW
1.260
MARKET CAP
34.96M
P/E (TTM)
-0.6249
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MLND stock price target is 4.333 with a high estimate of 5.00 and a low estimate of 3.000.

EPS

MLND News

More
Millendo Therapeutics Q2 EPS $(0.56) Up From $(0.74) YoY
Millendo Therapeutics (NASDAQ:MLND) reported quarterly losses of $(0.56) per share. This is a 24.32 percent increase over losses of $(0.74) per share from the same period last year.
Benzinga · 2d ago
Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Business Wire · 08/05 12:30
Millendo Therapeutics, Inc. (MLND): Hedge Funds Were Caught Flatfooted
Insider Monkey · 07/02 22:09
Millendo under pressure after bailing on nevanimibe
Seeking Alpha - Article · 06/23 15:56
Millendo Therapeutics Provides Corporate and Pipeline Update
Business Wire · 06/23 13:30
Millendo Provides Corporate And Pipeline Update; Says Has Engaged SVB Leerink To Support Strategic Review Process
– MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, advancing with first-in-human trials expected to initiate in 3Q20 – – Further investment in nevanimibe for congenital adrenal hyperplasia
Benzinga · 06/23 12:35
Millendo Provides Corporate And Pipeline Update; Says Has Engaged SVB Leerink To Support Strategic Review Process
– MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, advancing with first-in-human trials expected to initiate in 3Q20 – – Further investment in nevanimibe for congenital adrenal hyperplasia
Benzinga · 06/23 12:35
SSL, CCL among premarket losers
Seeking Alpha - Article · 06/18 12:51

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+1.37%

Hot Stocks

Symbol
Price
%Change

About MLND

Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.
More

Webull offers kinds of Millendo Therapeutics Inc stock information, including NASDAQ:MLND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MLND stock methods without spending real money on the virtual paper trading platform.